Novo Nordisk Cuts Forecast On US Pricing, NovoLog Contract Loss
Executive Summary
US payor pressure resulted in a big contract loss for Novo Nordisk’s blockbuster insulin NovoLog in the second quarter, prompting the Danish diabetes fighter to trim sales and profit forecasts for the full year.